AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30799375 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 27279571 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r 800/100 mg once daily)
Number of subjects: 273
Study 27279571 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 273
Study 27279571 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r)
Number of subjects: 273
Study 27279571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 273
Study 25988798 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose pentazocine/naloxone (50/0.5 mg)
Number of subjects: 12
Study 25988798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pentazocine/naloxone (25/0.25 mg)
Number of subjects: 12
Study 25988798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23750517 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTO (Parent Management Training Oregon model)
Number of subjects: 238
Study 23750517 — intervention group
Group type: COMPARATOR
Intervention: NTC (No Treatment Control)
Number of subjects: 238
Study 21449785 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management (diet)
Number of subjects: 107
Study 21449785 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 107
Study 21449785 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-management-Plus-Exercise (diet-exercise)
Number of subjects: 107
Study 21449785 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 107
Study 19922342 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (MLD)
Number of subjects: 32
Study 19922342 — intervention group
Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 32
Study 16858211 — intervention group
Group type: EXPERIMENTAL
Intervention: PL-irradiation (100%, 1800 mW)
Number of subjects: 24
Study 16858211 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise (50% HR reserve)
Number of subjects: 24
Study 16858211 — intervention group
Group type: COMPARATOR
Intervention: Placebo-irradiation (10%, 180 mW)
Number of subjects: 24
Study 12736838 — intervention group
Group type: EXPERIMENTAL
Intervention: Coper subjects
Number of subjects: 0
Study 12736838 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 12736838 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coper subjects
Number of subjects: 0
Study 10052484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (125-150 mg i.v.)
Number of subjects: 26
Study 7866820 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM (omeprazole 20 mg once in the morning, clarithromycin 250 mg and metronidazole 400 mg twice daily)
Number of subjects: 80
Study 7866820 — intervention group
Group type: COMPARATOR
Intervention: OCT (omeprazole 20 mg once in the morning, clarithromycin 250 mg and tetracycline 500 mg twice daily)
Number of subjects: 80
Study 7866820 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM
Number of subjects: 80
Study 7866820 — intervention group
Group type: COMPARATOR
Intervention: OCT
Number of subjects: 80
Study 1791389 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative instillation of 0.02% mitomycin-C
Number of subjects: 147
Study 1791389 — intervention group
Group type: COMPARATOR
Intervention: Beta radiation
Number of subjects: 147
Study 7338582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 59
Study 7338582 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 59
Study 31858823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pelvic floor muscle exercises and oscillating rod therapy
Number of subjects: 184
Study 31858823 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic floor muscle exercises and relaxation therapy
Number of subjects: 184
Study 11836674 — intervention group
Group type: COMPARATOR
Intervention: Active Symptom Control (ASC) alone
Number of subjects: 0
Study 11836674 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus mitomycin vinblastine and cisplatin (MVP)
Number of subjects: 0
Study 11836674 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC plus vinorelbine (N; Navelbine)
Number of subjects: 0
Study 29447133 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week online course of game‐like cognitive training exercises (3 sessions/week from home)
Number of subjects: 39
Study 29447133 — intervention group
Group type: COMPARATOR
Intervention: Active control involving watching documentary videos
Number of subjects: 39
Study 29447133 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cognitive training and control)
Number of subjects: 39
Study 26376944 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 90
Study 26376944 — intervention group
Group type: COMPARATOR
Intervention: One-Stage Full-Mouth Disinfection (FMD)
Number of subjects: 90
Study 24589824 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain and negative RTW-expectations
Number of subjects: 0
Study 24589824 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions
Number of subjects: 0
Study 24589824 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative RTW-expectations
Number of subjects: 0
Study 24589824 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 0
Study 22342864 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjury PUFAs (850 mg/d)
Number of subjects: 65
Study 20036067 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-tex bags
Number of subjects: 30
Study 20036067 — intervention group
Group type: COMPARATOR
Intervention: Traditional dressings
Number of subjects: 30
Study 18618204 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol counseling
Number of subjects: 288
Study 18618204 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol counseling)
Number of subjects: 288
Study 18618204 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of primary care
Number of subjects: 288
Study 16030123 — intervention group
Group type: EXPERIMENTAL
Intervention: Current/former smokers
Number of subjects: 772
Study 16030123 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with >=1 inactive GSTM1 alleles
Number of subjects: 772
Study 16030123 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with >=1 inactive GSTT1 alleles among smokers
Number of subjects: 772
Study 16030123 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with >=1 inactive GSTT1 alleles among never smokers
Number of subjects: 772
Study 12022301 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feeding (0.5‐1 ml h(‐1)) along with parenteral nutrition
Number of subjects: 80
Study 12022301 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition alone
Number of subjects: 80
Study 10526805 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.07 +/- 0.03 microgram.kg‐1.min‐1) during desflurane-N2O anesthesia
Number of subjects: 46
Study 10526805 — intervention group
Group type: COMPARATOR
Intervention: Control group (desflurane 2% and nitrous oxide 65%)
Number of subjects: 46
Study 8770775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose interleukin-2 (IL-2) at doses of 1, 3, and 6 x 10(6) IU/day, administered once daily 6 days a week for 12 weeks.
Number of subjects: 20
Study 8770775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose interleukin-2 (IL-2) at doses of 1, 3, and 6 x 10(6) IU/day.
Number of subjects: 20
Study 1827543 — intervention group
Group type: EXPERIMENTAL
Intervention: GR32191 (120 mg)
Number of subjects: 12
Study 1827543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6110040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine therapy (full-dose and maintenance) with food
Number of subjects: 0
Study 6110040 — intervention group
Group type: COMPARATOR
Intervention: Control (normal diet without cimetidine)
Number of subjects: 0
Study 30578395 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF21 levels at admission
Number of subjects: 509
Study 27808529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful-eating training
Number of subjects: 348
Study 27808529 — intervention group
Group type: COMPARATOR
Intervention: Nutrition DVD
Number of subjects: 348
Study 27808529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study 27459503 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE + SSSs
Number of subjects: 60
Study 27459503 — intervention group
Group type: COMPARATOR
Intervention: SSSs
Number of subjects: 60
Study 24571705 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge scheme
Number of subjects: 14
Study 24571705 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 14
Study 22991015 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions
Number of subjects: 182
Study 22991015 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD solutions (Control)
Number of subjects: 182
Study 21030879 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril titrated to 80 mg daily and additional antihypertensives to target SBP < 130 mm Hg
Number of subjects: 81
Study 16943794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg) on alternate days (ADs) for 4 weeks
Number of subjects: 20
Study 16943794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tadalafil administration
Number of subjects: 20
Study 16943794 — intervention group
Group type: COMPARATOR
Intervention: On-demand (OD) tadalafil administration
Number of subjects: 20
Study 16258088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (continuous infusion of 100 U/kg per day)
Number of subjects: 204
Study 16258088 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (50 mL/day as a continuous infusion)
Number of subjects: 204
Study 12099321 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional suturing
Number of subjects: 23
Study 12099321 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple V-Y suture
Number of subjects: 23
Study 12099321 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 23
Study 10345967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus omeprazole
Number of subjects: 819
Study 10345967 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 819
Study 10345967 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 819
Study 1318081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg/kg diazepam
Number of subjects: 66
Study 1318081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg diazepam
Number of subjects: 66
Study 1318081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2934803 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate mixed with lignocaine
Number of subjects: 30
Study 2934803 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 30
Study 31741553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dexamethasone (8 mg) and levobupivacaine (12.5 mg, 0.5%)
Number of subjects: 60
Study 31741553 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (12.5 mg, 0.5%)
Number of subjects: 60
Study 29223101 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation Anaesthesia (IA)
Number of subjects: 0
Study 29223101 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 0
Study 27127650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 37°C
Number of subjects: 10
Study 27127650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 41°C
Number of subjects: 10
Study 27127650 — intervention group
Group type: COMPARATOR
Intervention: Nasal high flow therapy at 37°C and 41°C
Number of subjects: 10
Study 25803270 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 18
Study 25803270 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 18
Study 23868944 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 58
Study 23868944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 58
Study 20544245 — intervention group
Group type: EXPERIMENTAL
Intervention: CYC
Number of subjects: 24
Study 20544245 — intervention group
Group type: EXPERIMENTAL
Intervention: CYC + PRED
Number of subjects: 24
Study 19177949 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory model
Number of subjects: 80
Study 19177949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked‐blocked and blocked‐random practice conditions
Number of subjects: 80
Study 19177949 — intervention group
Group type: EXPERIMENTAL
Intervention: Random‐random and blocked‐random practice schedules
Number of subjects: 80
Study 19177949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked‐random practice condition
Number of subjects: 80
Study 16982936 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination (inactivated vaccine, administered intramuscularly)
Number of subjects: 0
Study 16982936 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccination (live, attenuated vaccine, administered intranasally)
Number of subjects: 0
Study 14582335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 160
Study 14582335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pirymethamine (SDXP)
Number of subjects: 160
Study 14582335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (SDXP/CQ)
Number of subjects: 160
Study 14582335 — intervention group
Group type: EXPERIMENTAL
Intervention: Late treatment failure (asymptomatic)
Number of subjects: 160
Study 11022900 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 106
Study 11022900 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication
Number of subjects: 106
Study 9190662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine
Number of subjects: 40
Study 9190662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9190662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine with psychotherapy
Number of subjects: 40
Study 9190662 — intervention group
Group type: COMPARATOR
Intervention: Placebo with psychotherapy
Number of subjects: 40
Study 9190662 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of lidamidine vs placebo
Number of subjects: 40
Study 7965900 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential design
Number of subjects: 134
Study 7965900 — intervention group
Group type: COMPARATOR
Intervention: Bar design
Number of subjects: 134
Study 7965900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both designs
Number of subjects: 134
Study 3315593 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 43
Study 3315593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31935249 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-adjusted dose of palonosetron (1 μg/kg, GI = 40 patients)
Number of subjects: 80
Study 31935249 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of palonosetron (75 μg, GII = 40 patients)
Number of subjects: 80
Study 31935249 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-adjusted dose of palonosetron (1 μg/kg, GI)
Number of subjects: 80
Study 31935249 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of palonosetron (75 μg, GII)
Number of subjects: 80
Study 29239763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Action Tourniquet (CAT)
Number of subjects: 198
Study 29239763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratcheting Medical Tourniquet (RMT)
Number of subjects: 198
Study 29239763 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch Wrap and Tuck Tourniquet (SWAT‐T)
Number of subjects: 198
Study 27398991 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking shoes with triple‐density, variable‐stiffness midsoles and mild lateral‐wedge insoles worn daily
Number of subjects: 164
Study 27398991 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking shoes
Number of subjects: 164
Study 24762371 — intervention group
Group type: COMPARATOR
Intervention: Usual education at the time of hospital discharge
Number of subjects: 110
Study 24762371 — intervention group
Group type: EXPERIMENTAL
Intervention: Special education by nurses during home visits in addition to usual education
Number of subjects: 110
Study 24762371 — intervention group
Group type: EXPERIMENTAL
Intervention: Special education by nurses during home visits
Number of subjects: 110
Study 23163490 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) scans
Number of subjects: 453
Study 23163490 — intervention group
Group type: EXPERIMENTAL
Intervention: Caliper measurement of centerpoint thickness (CPT)
Number of subjects: 453
Study 20166156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO(2) laser treatment
Number of subjects: 28
Study 20166156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser treatment
Number of subjects: 28
Study 20166156 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the comparison between CO(2) and Er:YAG)
Number of subjects: 28
Study 18296026 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Health Improvement Project (CHIP) intervention group
Number of subjects: 348
Study 15713002 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood orange juice (600 mL/day)
Number of subjects: 16
Study 15713002 — intervention group
Group type: COMPARATOR
Intervention: Diet without juice
Number of subjects: 16
Study 12969212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/day for 5 days) plus standard care
Number of subjects: 52
Study 12969212 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 52
Study 9869719 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 43
Study 9869719 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 43
Study 8886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone 0.25 U/kg/week (subdivided in daily subcutaneous injections, starting with half the dosage for the first four weeks)
Number of subjects: 20
Study 8886750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone 0.25 U/kg/week
Number of subjects: 20
Study 8886750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1352564 — intervention group
Group type: EXPERIMENTAL
Intervention: UW preservation solution
Number of subjects: 695
Study 1352564 — intervention group
Group type: COMPARATOR
Intervention: EuroCollins solution
Number of subjects: 695
Study 6385759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 1 of ethyl alcohol resulting in a peak BAC of 100 mg/100 ml
Number of subjects: 48
Study 6385759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 2 of ethyl alcohol administered when BAC had fallen to one-half the peak BAC from dose 1
Number of subjects: 48
Study 6385759 — intervention group
Group type: COMPARATOR
Intervention: Placebo doses administered to five brother-pairs (controls)
Number of subjects: 48
Study 30206728 — intervention group
Group type: COMPARATOR
Intervention: Post-infusion scalp cooling for 90 minutes
Number of subjects: 102
Study 30206728 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-infusion scalp cooling for 150 minutes
Number of subjects: 102
Study 29602791 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (CANA)
Number of subjects: 36
Study 29602791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA)
Number of subjects: 36
Study 29602791 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin plus Liraglutide (CANA/LIRA)
Number of subjects: 36
Study 26582520 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (BeInCharge.org [BIC])
Number of subjects: 10
Study 26582520 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Control (STC)
Number of subjects: 10
Study 25128520 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly plus Methotrexate (MTX)
Number of subjects: 0
Study 25128520 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 0
Study 22325110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg norethindrone (NET)
Number of subjects: 33
Study 22325110 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg norethindrone (NET)
Number of subjects: 33
Study 19559380 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (n=42,590)
Number of subjects: 84781
Study 19559380 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=42,191)
Number of subjects: 84781
Study 17148582 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse ATG/Cyclosporine (HC)
Number of subjects: 78
Study 17148582 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse ATG/Cyclosporine/Sirolimus (HCS)
Number of subjects: 78
Study 17148582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit ATG/Cyclosporine (RC)
Number of subjects: 78
Study 17148582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (CP)
Number of subjects: 78
Study 16167234 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA enriched formula
Number of subjects: 40
Study 16167234 — intervention group
Group type: COMPARATOR
Intervention: Routine amino acid
Number of subjects: 40
Study 11980678 — intervention group
Group type: EXPERIMENTAL
Intervention: phVEGF2 (200 microg, 800 microg, or 2000 microg)
Number of subjects: 19
Study 11980678 — intervention group
Group type: EXPERIMENTAL
Intervention: phVEGF2
Number of subjects: 19
Study 11980678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9460820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program for Type A behavior
Number of subjects: 47